Original Articles
Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose
Matthew D. Snape, Praveen Saroey, Tessa M. John, Hannah Robinson, Sarah Kelly, Nicoletta Gossger, Ly-Mee Yu, Huajun Wang, Daniela Toneatto, Peter M. Dull and Andrew J. Pollard
CMAJ September 23, 2013 cmaj.130257; DOI: https://doi.org/10.1503/cmaj.130257
Matthew D. Snape
The Department of Paediatrics (Snape, Saroey, John, Robinson, Kelly, Gossger, Pollard), University of Oxford and NIHR (National Institute for Health Research) Oxford Biomedical Research Centre, Oxford, United Kingdom; Centre for Statistics in Medicine (Yu), University of Oxford, Oxford, United Kingdom; and Novartis Vaccines and Diagnostics (Wang, Toneatto, Dull), Siena, Italy
Praveen Saroey
The Department of Paediatrics (Snape, Saroey, John, Robinson, Kelly, Gossger, Pollard), University of Oxford and NIHR (National Institute for Health Research) Oxford Biomedical Research Centre, Oxford, United Kingdom; Centre for Statistics in Medicine (Yu), University of Oxford, Oxford, United Kingdom; and Novartis Vaccines and Diagnostics (Wang, Toneatto, Dull), Siena, Italy
Tessa M. John
The Department of Paediatrics (Snape, Saroey, John, Robinson, Kelly, Gossger, Pollard), University of Oxford and NIHR (National Institute for Health Research) Oxford Biomedical Research Centre, Oxford, United Kingdom; Centre for Statistics in Medicine (Yu), University of Oxford, Oxford, United Kingdom; and Novartis Vaccines and Diagnostics (Wang, Toneatto, Dull), Siena, Italy
Hannah Robinson
The Department of Paediatrics (Snape, Saroey, John, Robinson, Kelly, Gossger, Pollard), University of Oxford and NIHR (National Institute for Health Research) Oxford Biomedical Research Centre, Oxford, United Kingdom; Centre for Statistics in Medicine (Yu), University of Oxford, Oxford, United Kingdom; and Novartis Vaccines and Diagnostics (Wang, Toneatto, Dull), Siena, Italy
Sarah Kelly
The Department of Paediatrics (Snape, Saroey, John, Robinson, Kelly, Gossger, Pollard), University of Oxford and NIHR (National Institute for Health Research) Oxford Biomedical Research Centre, Oxford, United Kingdom; Centre for Statistics in Medicine (Yu), University of Oxford, Oxford, United Kingdom; and Novartis Vaccines and Diagnostics (Wang, Toneatto, Dull), Siena, Italy
Nicoletta Gossger
The Department of Paediatrics (Snape, Saroey, John, Robinson, Kelly, Gossger, Pollard), University of Oxford and NIHR (National Institute for Health Research) Oxford Biomedical Research Centre, Oxford, United Kingdom; Centre for Statistics in Medicine (Yu), University of Oxford, Oxford, United Kingdom; and Novartis Vaccines and Diagnostics (Wang, Toneatto, Dull), Siena, Italy
Ly-Mee Yu
The Department of Paediatrics (Snape, Saroey, John, Robinson, Kelly, Gossger, Pollard), University of Oxford and NIHR (National Institute for Health Research) Oxford Biomedical Research Centre, Oxford, United Kingdom; Centre for Statistics in Medicine (Yu), University of Oxford, Oxford, United Kingdom; and Novartis Vaccines and Diagnostics (Wang, Toneatto, Dull), Siena, Italy
Huajun Wang
The Department of Paediatrics (Snape, Saroey, John, Robinson, Kelly, Gossger, Pollard), University of Oxford and NIHR (National Institute for Health Research) Oxford Biomedical Research Centre, Oxford, United Kingdom; Centre for Statistics in Medicine (Yu), University of Oxford, Oxford, United Kingdom; and Novartis Vaccines and Diagnostics (Wang, Toneatto, Dull), Siena, Italy
Daniela Toneatto
The Department of Paediatrics (Snape, Saroey, John, Robinson, Kelly, Gossger, Pollard), University of Oxford and NIHR (National Institute for Health Research) Oxford Biomedical Research Centre, Oxford, United Kingdom; Centre for Statistics in Medicine (Yu), University of Oxford, Oxford, United Kingdom; and Novartis Vaccines and Diagnostics (Wang, Toneatto, Dull), Siena, Italy
Peter M. Dull
The Department of Paediatrics (Snape, Saroey, John, Robinson, Kelly, Gossger, Pollard), University of Oxford and NIHR (National Institute for Health Research) Oxford Biomedical Research Centre, Oxford, United Kingdom; Centre for Statistics in Medicine (Yu), University of Oxford, Oxford, United Kingdom; and Novartis Vaccines and Diagnostics (Wang, Toneatto, Dull), Siena, Italy
Andrew J. Pollard
The Department of Paediatrics (Snape, Saroey, John, Robinson, Kelly, Gossger, Pollard), University of Oxford and NIHR (National Institute for Health Research) Oxford Biomedical Research Centre, Oxford, United Kingdom; Centre for Statistics in Medicine (Yu), University of Oxford, Oxford, United Kingdom; and Novartis Vaccines and Diagnostics (Wang, Toneatto, Dull), Siena, Italy
Online Appendices
- Appendix 1: Reverse cumulative distribution curves for hSBA titres at baseline and following the first dose of vaccine
- Appendix 2: hSBA geometric mean titres for all visits in the original study and follow-up study
- Appendix 3: Local reactogenicity following administration of 4CMenB (3a) and rMenB (3b).
- Appendix 4: Systemic reactogenicity of 4CMenB (4a) and rMenB (4b).